Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Omega-3 Fatty Acids Linked to BP Reductions, Meta-analysis Hints

L.A. McKeown

June 06, 2022

News Daily News

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Yael L. Maxwell

February 17, 2022

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

Todd Neale

June 22, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

Advertisement

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Omega-3 Fatty Acids Linked to BP Reductions, Meta-analysis Hints

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Recurrent Events Common Among Young Patients With CAD

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content